A Case of Acquired Fanconi Syndrome Induced by Zoledronic Acid
|
|
- Blanche Stokes
- 5 years ago
- Views:
Transcription
1 CASE REPORT A Case of Acquired Fanconi Syndrome Induced by Zoledronic Acid Tetsuhiro Yoshinami, Toshinari Yagi, Daisuke Sakai, Naotoshi Sugimoto and Fumio Imamura Abstract A 61-year-old woman with metastatic breast cancer was diagnosed as having acquired Fanconi syndrome. In this case, the cause of this syndrome was most likely zoledronic acid (Zometa ), which had been infused intravenously at a dose of 4 mg over 15 minutes weekly because of malignancy-associated hypercalcemia. Zoledronic acid is nephrotoxic and may induce severe tubular dysfunction, which can cause development of Fanconi syndrome. Therefore, close monitoring of proximal tubular function is recommended during therapy with zoledronic acid, especially when frequent administration of zoledronic acid is needed. Key words: Fanconi syndrome, zoledronic acid, metastatic breast cancer, nephrotoxicity () () Introduction Fanconi syndrome is a generalized dysfunction of the renal proximal tubules, which causes renal losses of glucose, protein, bicarbonates, calcium, uric acid, amino acids, and other organic compounds (1). As a result, various abnormalities are found on examination of blood and urine. Zoledronic acid (Zometa ) is one of the nitrogen-containing bisphosphonates. It is effective in the treatment of hypercalcemia and bone metastasis, and widely used for various malignancies (2). However, it has been reported to be nephrotoxic (3-5), and several cases of acute tubular necrosis due to zoledronic acid have been reported (3). We encountered a breast cancer patient who developed Fanconi syndrome due to zoledronic acid. To our knowledge, this is the first case report describing Fanconi syndrome due to zoledronic acid. Case Report A 61-year-old woman with metastatic breast cancer was admitted to our hospital because of hypokalemia at the end of December She was anorexic but findings on physical examination were normal. She had been diagnosed as having breast cancer (T3N1M0 Stage IIIA, Estrogen receptor-, Progesteron receptor-,her2 3+) in January 2009, and received 4 courses of FEC (5-FU 500 mg/m 2 on day 1, epirubicin 100 mg/m 2 on day 1 and cyclophosphamide 500 mg/m 2 on day 1, repeated every 21 days) followed by 4 courses of docetaxel (75 mg/m 2, repeated every 21 days) as neo-adjuvant chemotherapy. Then breast-conserving surgery and axillary lymph node dissection was performed in mid-august On postoperative pathological examination, the efficacy of neoadjuvant chemotherapy was judged as grade 2 (6). At the end of September 2009, she was hospitalized because of malignancy-associated hypercalcemia (MAHC) due to metastatic breast cancer. Serum calcium concentration was 17.2 mg/dl (normal range, mg/dl), and serum albumin concentration was 2.9 mg/dl (normal range, g/dl). Metastasis to the liver from breast cancer was detected by computed tomography (CT) on admission. For MAHC, she received repeated intravenous injections of zoledoronic acid (Zometa ) at a dose of 4 mg infused over 15 minutes administered weekly from the end of Sept till the end of November Combination chemotherapy of paclitaxel (30 mg/m 2, repeated weekly) and trastuzumab (2 mg/kg, repeated weekly after the first loading dose of 4 mg/kg) was started at the end of October MAHC was improved by zoledronic acid and the chemotherapy. In early December 2009, she was discharged but returned once a week to continue the chemotherapy. Department of Clinical Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan Received for publication November 15, 2010; Accepted for publication January 17, 2011 Correspondence to Dr. Tetsuhiro Yoshinami, yosinami-te@mc.pref.osaka.jp 1075
2 Table 1. Laboratory Examination on Admission Blood examination on re-admission in December 2009 demonstrated hypokalemia, hypophosphatemia and hypouricemia (Table 1). Chemical screening of urine showed glucosuria (2+) and proteinuria (3+: 24-h urinary protein was 0.9 g). Despite glucosuria, routine blood glucose was 117 mg/dl and HbA1c was 4.7%, indicating that the cause of glucosuria was renal diabetes. Urinary examinations demonstrated that 24-h urinary potassium excretion was increased to 26.5 meq/day, and urinary anion gap was 27.2 meq/l. Fractional excretion of uric acid was 56% (normal range, 6% to 20%) and TmPO4/GFR was 0.75 (normal range, 2.3 to 4.3). Urinary β2-microglobulin (β2mg) value was 69,264 μg/day (normal range, μg/day), which was equivalent to 197,897 μg/g Cr. Blood gas analysis showed a pattern of hyperchloremic metabolic acidosis. Bicarbonate concentration was decreased to 16.4 mmol/l, but respiratory compensation normalized the ph. Ten days after admission, adjusted serum calcium concentration was 7.5 mg/dl (serum calcium and albumin concentration were 6.1 mg/dl and 2.6 g/dl respectively), indicating hypocalcemia. Since Fanconi syndrome was suspected based on the above findings, urinary amino acid analysis was conducted. Urinary concentrations of 23 of 41 amino acids were increased (Table 2). The diagnosis of Fanconi syndrome was established by hyperaminoaciduria, renal diabetes, phosphaturia and hypophosphatemia, hyperchloremic metabolic acidosis, proteinuria, and other characteristic electrolyte abnormalities of blood and urine. Oral intake of spironolactone successfully increased the serum potassium concentration to a normal level. Intravenous or oral administration of sodium bicarbonate improved metabolic acidosis (Fig. 1), and anorexia disappeared. She was discharged at the end of January In this case, the cause of Fanconi syndrome was most likely drug related. Possible causative drugs were zoledronic acid, paclitaxel and trastuzumab. This patient stopped receiving injections of zoledronic acid after the end of November However, her breast cancer was so advanced that continued administration of combined chemotherapy with paclitaxel and trastuzumab was necessary. She continued the ambulatory chemotherapy with paclitaxel and trastuzumab, supported by oral spironolactone and sodium bicarbonate. Urinary protein and glucose became undetectable, and urinary β2-microglobulin gradually decreased to 1,415 μg/g Cr on May 2010, indicating the improvement of Fanconi syndrome. Discussion Fanconi syndrome was first described by Lignac in 1924 (1). It is characterized by multiple transport defects in the renal proximal tubules. The dysfunction leads to renal losses of glucose, protein, amino acids, bicarbonates, uric acid, and some electrolytes such as sodium, potassium, calcium, and phosphate. Cardinal features of the syndrome are hyperaminoaciduria, glucosuria despite a normal serum glucose level, phosphate wasting (phosphaturia and hypophosphatemia), acidosis, and proteinuria. Other manifestations are hypouricemia, hypokalemia, hyponatremia, hypercalciuria, and polyuria. In the present case, proteinuria, renal diabetes, hyperchloremic metabolic acidosis, hypophosphatemia and some other electrolyte abnormalities were found, which strongly suggested Fanconi syndrome. Diagnosis of Fanconi syndrome was confirmed by the demonstration of hyperaminoaciduria. Causes of Fanconi syndrome range from inherited diseases to acquired factors. Inherited diseases such as cystinosis, galactosemia and Wilson s disease are known to be associated with this syndrome. Certain drugs including cisplatin, ifosphamide, gentamicin sulfate and valproate sodium are reported to contribute to the development of the syn- 1076
3 Table 2. Urinary Amino Acid Analysis drome. Other causative factors include heavy metals, such as lead and cadmium and systemic disorders, such as amyloidosis, multiple myeloma and systemic lupus erythematosus. In the present case, Fanconi syndrome was thought to have been induced by zoledronic acid. The abnormalities on blood and urine examinations associated with the syndrome had not been detected before the administration of zoledronic acid, and she did not have any history of illness other than breast cancer. Based on the Naranjo Adverse Drug Reaction probability scale, a drug reaction is the probable cause of the syndrome in the present case (7). The last administration of zoledronic acid was at the end of November 2009, and Fanconi syndrome gradually improved following the discontinuation of zoledronic acid despite the continuation of other drugs. We concluded that zoledronic acid was the cause of Fanconi syndrome in this case. We cannot rule out a possibility that paclitaxel or trastuzumab may have increased nephrotoxicity of zoledronic acid. A retrospective analysis showed an increased nephrotoxicity in patients with gynecological cancers treated with paclitaxel and cisplatin as compared to those receiving cisplatin alone (8). However, we cannot find any other report suggesting an association between paclitaxel or trastuzumab and nephrotoxicity, and based on the Drug Interaction Probability Scale, the role of paclitaxel or trastuzumab in this event is doubtful (9). Zoledronic acid (Zometa ) is one of the nitrogencontaining bisphosphonates. It inhibits bone resorption, resulting in not only the improvement of MAHC but also a reduction of the risk of skeletal-related events in solid cancer patients (10-13). Significant side effects of bisphosphonates are relatively rare, but these agents are nephrotoxic (3, 4, 14). In general, patterns of nephrotoxicity include toxic acute tubular necrosis (ATN) and collapsing focal segmental glomerulosclerosis (FSGS) (4). The nephrotoxicity of zoledronic acid appears to be associated mainly with injury to the tubules (4). Markowitz et al reported 6 cases of ATN, five with multiple myeloma and one with 1077
4 Figure 1. The left axis shows UA (mg/dl), K (meq/l) and IP (meq/l). The right axis shows HCO 3 (mmol/l). Hypokalemia, hypophosphatemia and metabolic acidosis were improved by therapies such as oral intake of spironolactone and administration of sodium bicarbonate after admission. Paget s disease, treated with zoledronic acid (3). All six patients received intravenous monthly administration of 4 mg zoledronic acid, infused over 15 minutes. They developed renal failure with a rise in serum creatinine. Renal biopsy demonstrated toxic ATN without evidence of collapsing FSGS. The frequency and severity of nephrotoxicity of zoledronic acid depends on the length of infusion time and dosage (5). In the early clinical trials with zoledronic acid, two protocol adjustments were required to reduce its renal toxicity (11-13). One was to increase the infusion time period from 5 to 15 minutes, and the other was to reduce the dose from 8 to 4 mg every 3 to 4 weeks. Currently, it is recommended that zoledronic acid be intravenously infused at a dose of 4 mg over 15 minutes. The interval between each administration is at least a week for treatment of MAHC and 3 or 4 weeks for the treatment of skeletal metastases in patients with multiple myeloma and solid tumors. The present patient received weekly administrations of 4 mg zoledronic acid via a 15-minute infusion because MAHC was so severe that she needed to receive treatment as frequently as possible. Zoledronic acid administration was performed nine times over approximately two months. Such frequent administrations might have increased the risk of renal injury. Buysschaert et al reported a case of Fanconi syndrome induced by intravenous pamidronate (15), which is also one of the bisphosphonates and has been shown to be more nephrotoxic than zoledronic acid in rat models (16). However, there has not been any case of zoledronic acid induced-fanconi syndrome reported to date. In conclusion, zoledronic acid can induce severe tubular dysfunction, which may progress to Fanconi syndrome. Therefore, close monitoring of proximal tubular function is recommended during therapy with zoledronic acid as well as pamidronate, especially when frequent administration is needed. The authors state that they have no Conflict of Interest(COI). References 1. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Druginduced Fanconi s syndrome. Am J Kidney Dis 41: , Kawada K, Minami H, Okabe K, et al. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Jpn J Clin Oncol 35: 28-33, Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate. Kidney Int 64: , Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 74: , Pfister T, Atzpodien E, Bohrmann B, Bauss F. Acute renal effects of intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol 97: , The Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer (the 16th edition). (in Japanese). 1078
5 7. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: , Merouani A, Davidson SA, Schrier RW. Increased nephrotoxicity of combination Taxol and Cisplatin chemotherapy in gynecologic cancers as compared to Cisplatin alone. Am J Nephrol 17: 53-58, Horm JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 41: , Major PP, Coleman RE. Zoledronic acid in treatment of hypercalcemia of malignancy: Results of the International Clinical Development Program. Semin Oncol 28 (Suppl 6): 17-24, Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind comparative trial. Cancer J 7: , Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastatic in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21: , Rosen LS, Gordon D, Tchekmedyian S, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer 100: , Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 349: , Buysschaert M, Cosyns JP, Barreto L, Ladoul M. Pamidronateinduced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant 18: , Green JR, Seltenmeyer Y, Jaeggi KA, Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 80: , The Japanese Society of Internal Medicine
Renal Tubular Acidosis
1 Renal Tubular Acidosis Mohammad Tariq Ibrahim 6 th Grade Diyala College Of Medicine supervisor DR. Sabah Almaamoory 2 *Renal Tubular Acidosis:- RTA:- is a disease state characterized by a normal anion
More informationBone Metastases. Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital
Bone Metastases Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital 1 Outline Pathophysiology Signs & Symptoms Diagnosis Treatment Spinal Cord Compression 2 General Information
More informationRENAL TUBULAR ACIDOSIS An Overview
RENAL TUBULAR ACIDOSIS An Overview UNIVERSITY OF PNG SCHOOL OF MEDICINE AND HEALTH SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY CLINICAL BIOCHEMISTRY PBL MBBS IV VJ. Temple 1 What is Renal Tubular
More informationBisphosphonate nephrotoxicity
http://www.kidney-international.org & 2008 International Society of Nephrology review Bisphosphonate nephrotoxicity Mark A. Perazella 1 and Glen S. Markowitz 2 1 Section of Nephrology, Yale University
More informationAnna Vinnikova, M.D. Division of Nephrology Virginia Commonwealth University
Metabolic Acidosis Anna Vinnikova, M.D. Division of Nephrology Virginia Commonwealth University Graphics by permission from The Fluid, Electrolyte and Acid-Base Companion, S. Faubel and J. Topf, http://www.pbfluids.com
More informationProlonged Recovery Time from Zoledronic Acid Induced Acute Tubular Necrosis: A Case Report and Review of the Literature
Prolonged Recovery Time from Zoledronic Acid Induced Acute Tubular Necrosis: A Case Report and Review of the Literature Frederic Rahbari Oskoui, Emory University Odicie Fielder, Harbor-UCLA Medical Center
More informationURINARY NET CHARGE IN HYPERCHLOREMIC METABOLIC ACIDOSIS. Seema Kumar, Meera Vaswani*, R.N. Srivastava and Arvind Bagga
INDIAN PEDIATRICS VOLUME 35-JANUARY 1998 Original Articles URINARY NET CHARGE IN HYPERCHLOREMIC METABOLIC ACIDOSIS Seema Kumar, Meera Vaswani*, R.N. Srivastava and Arvind Bagga From the Departments of
More informationEfficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with Advanced Cancer
Review Articles Jpn J Clin Oncol 2012;42(8)663 669 doi:10.1093/jjco/hys088 Advance Access Publication 13 June 2012 Efficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with
More informationClodronate BE/H/PSUR/001/001 October 2011 Agreed CSP
Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Intravenous use Treatment of hypercalcemia due to malignancy. Oral use Treatment of hypercalcemia
More informationTarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT
The Kidney in Multiple Myeloma Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT Normal Cell Plasma cells produce antibodies that bind to antigens,
More informationHYPERCALCEMIA. Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra hospital, Isfahan university of medical sciences
HYPERCALCEMIA Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra hospital, Isfahan university of medical sciences ESSENTIALS OF DIAGNOSIS Serum calcium level > 10.5 mg/dl Serum ionized
More informationThe Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer
City Wide Medical Oncology Rounds Friday Sept. 21 st, 2007 The Latest is the Greatest Future Directions in the Management of Patients with Bone Metastases from Breast Cancer Mark Clemons Head, Breast Medical
More informationCCRN Review - Renal. CCRN Review - Renal 10/16/2014. CCRN Review Renal. Sodium Critical Value < 120 meq/l > 160 meq/l
CCRN Review Renal Leanna R. Miller, RN, MN, CCRN-CMC, PCCN-CSC, CEN, CNRN, CMSRN, NP Education Specialist LRM Consulting Nashville, TN Sodium 136-145 Critical Value < 120 meq/l > 160 meq/l Sodium Etiology
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationIbandronate: Its Role in Metastatic Breast Cancer
Ibandronate: Its Role in Metastatic Breast Cancer David Cameron, a Marie Fallon, a Ingo Diel b a Western General Hospital, Edinburgh, United Kingdom; b Institute for Gynecological Oncology, Mannheim, Germany
More informationBisphosphonates and RANK-L inhibitors in Myeloma
Bisphosphonates and RANK-L inhibitors in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationBCCA Protocol Summary Guidelines for the Diagnosis and Management of Malignancy Related Hypercalcemia
BCCA Protocol Summary Guidelines for the Diagnosis and Management of Malignancy Related Hypercalcemia Protocol Code Tumour Group Supportive Care Group Contacts SCHYPCAL Supportive Care Lisa Wanbon (VIC)
More informationOncologist. The. Symptom Management and Supportive Care. Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid
The Oncologist Symptom Management and Supportive Care Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid JAMES BERENSON, a RAIMUND HIRSCHBERG b a Cedars-Sinai Medical Center, Los Angeles,
More informationDisodium pamidronate for treating severe hypercalcemia in a hemodialysis patient
Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient Hernán Trimarchi, Fernando Lombi, Mariano Forrester, Cristina Elizondo, Deirdre Sawinski, Horacio Pereyra and Emilio Freixas
More informationRifampin-associated tubulointersititial nephritis and Fanconi syndrome presenting as hypokalemic paralysis
Min et al. BMC Nephrology 2013, 14:13 CASE REPORT Open Access Rifampin-associated tubulointersititial nephritis and Fanconi syndrome presenting as hypokalemic paralysis Hong Ki Min 1, Eun Oh Kim 1, Sang
More informationSetting The study setting was secondary care. The economic study was undertaken in Spain.
Zoledronic acid versus pamidronate: cost minimisation in bone metastasis Slof J, Badia X, Lizan L, Bautista F J, Echarri E, Hurle A D, Pla R, Mangues M A, Rodriguez-Sasiain J M, Wood M A Record Status
More informationAETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents
AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents Injectable Osteoporosis Agents Forteo (teriparatide); zoledronic acid Prolia (denosumab)] Authorization guidelines For
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationEfficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data
Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data Richard Bell The Andrew Love Cancer Centre Cancer Services, Medical Oncology, Geelong, Victoria, Australia Key Words. Bisphosphonate
More informationPreclinical Perspectives on Bisphosphonate Renal Safety
Preclinical Perspectives on Bisphosphonate Renal Safety Jean-Jacques Body, a Thomas Pfister, b Frieder Bauss c a Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; b Pre-clinical
More informationElevated Serum Creatinine, a simplified approach
Elevated Serum Creatinine, a simplified approach Primary Care Update Creighton University School of Medicine. April 27 th, 2018 Disclosure Slide I have no disclosures and have no conflicts with this presentation.
More informationWATER, SODIUM AND POTASSIUM
WATER, SODIUM AND POTASSIUM Attila Miseta Tamás Kőszegi Department of Laboratory Medicine, 2016 1 Average daily water intake and output of a normal adult 2 Approximate contributions to plasma osmolality
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationDiuretic Use in Neonates
Neonatal Nursing Education Brief: Diuretic Use in the Neonate http://www.seattlechildrens.org/healthcareprofessionals/education/continuing-medical-nursing-education/neonatalnursing-education-briefs/ Diuretics
More informationOUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH NON- SMALL CELL LUNG CANCER AND BONE METASTASES
ISSN: 1312-773X (Online) DOI: 10.5272/jimab.2013191.391 Journal of IMAB - Annual Proceeding (Scientific Papers) 2013, vol. 19, issue 1 OUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH
More informationCase Studies: Renal and Urologic Impairments Workshop
Case Studies: Renal and Urologic Impairments Workshop Justine Lee, MD, DBIM New York Life Insurance Co. Gina Guzman, MD, DBIM, FALU, ALMI Munich Re AAIM Triennial October, 2012 The Company You Keep 1 Case
More informationA Case Report of Deferasirox-induced Kidney Injury and Fanconi Syndrome
CASE REPORT A Case Report of Deferasirox-induced Kidney Injury and Fanconi Syndrome Noreen Murphy, MD; Mohsen Elramah, MD; Hemender Vats, MD; Weixong Zhong, MD, PhD; Micah R. Chan, MD MPH ABSTRACT Cases
More informationRenal Transporters- pathophysiology of drug - induced renal disorders. Lisa Harris, Pharmacist, John Hunter Hospital, Newcastle, 2015 November
Renal Transporters- pathophysiology of drug - induced renal disorders Lisa Harris, Pharmacist, John Hunter Hospital, Newcastle, 2015 November Renal Failure Up to 25% of acute renal failure is drug induced
More informationPublished Ahead of Print on May 2, 2009 as /theoncologist
The Oncologist Symptom Management and Supportive Care High Incidence of Hypocalcemia and Serum Creatinine Increase in Patients with Bone Metastases Treated with Zoledronic Acid MONICA ZURADELLI, a GIOVANNA
More informationTUBULOPATHY Intensive Care Unit Sina Hospital
TUBULOPATHY Intensive Care Unit Sina Hospital A 13 years old female who is known case of Scoliosis. She was operated 2 months ago for spinal curve repair. PMH:EMG-MCV In 2 years old =>No Motoneuron Disease
More information亞東紀念醫院 Breast Cancer 化學治療處方集
亞東紀念醫院 Breast Cancer 化學治療處方集 2008-08 制定 最近修改日期 :2015-01 CMF Breast cancer 化學治療處方參考集 Adjuvant Classic CMF Cyclophosphamide 100mg/m2 PO qd; D1-D14 Methotrexate 40mg/m 2 in N/S 100 ml IV drip 30 mins; D1,
More informationTDF Renal Dysfunction
TDF Renal Dysfunction Sarala Naicker MBChB, FRCP, PhD Division of Nephrology Dept of Internal Medicine University of the Witwatersrand Johannesburg South Africa SA HIV Clinician Society Conference Cape
More informationApproach to a patient with hypercalcemia
Approach to a patient with hypercalcemia Ana-Maria Chindris, MD Division of Endocrinology Mayo Clinic Florida 2013 MFMER slide-1 Background Hypercalcemia is a problem frequently encountered in clinical
More informationINTRAVENOUS FLUIDS PRINCIPLES
INTRAVENOUS FLUIDS PRINCIPLES Postnatal physiological weight loss is approximately 5-10% Postnatal diuresis is delayed in Respiratory Distress Syndrome (RDS) Preterm babies have limited capacity to excrete
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationDepartment of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Department of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India Evidence-Based Pragmatic SGPGI Breast Cancer Management Protocols (Summary) Background:
More informationMITO Renal Agnès Rötig Patrick Niaudet
MITO 101 - Renal Agnès Rötig Patrick Niaudet INSERM U781 and Service de Néphrologie Pédiatrique, Necker Hospital, Université Paris V- René Descartes, Paris, France Renal involvement is not a common feature
More informationBisphosphonate-induced Severe Hypocalcemia - A Case Report -
CASE REPORT http://dx.doi.org/10.11005/jbm.2012.19.2.139 Vol. 19, No. 2, 2012 Bisphosphonate-induced Severe Hypocalcemia - A Case Report - Won-Seok Do, Jin-Kyung Park, Myung-Il Park, Hyeong-Seok Kim, Sung-Ho
More informationNon-Anion Gap Metabolic Acidosis. App.GoSoapbox.com then Join Now. Joel M. Topf, M.D.
Non-Anion Gap Metabolic Acidosis App.GoSoapbox.com 665-971-584 then Join Now Joel M. Topf, M.D. http://pbfluids.com @kidney_boy App.GoSoapbox.com 665-971-584 32 y.o. female with fatigue, weakness and muscle
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationRenal Tubular Acidosis in Patients with Primary Sjögren s Syndrome
Case Report ISSN 1738-5997 (Print) ISSN 2092-9935 (Online) Electrolyte Blood Press 15:17-22, 2017 https://doi.org/10.5049/ebp.2017.15.1.17 Renal Tubular Acidosis in Patients with Primary Sjögren s Syndrome
More informationJo Abraham MD Division of Nephrology University of Utah
Jo Abraham MD Division of Nephrology University of Utah 68 year old male presented 3 weeks ago with a 3 month history of increasing fatigue He reported a 1 week history of increasing dyspnea with a productive
More informationBISPHOSPHONATES ARE POTENT INHIBITORS of normal and. A Dose-Finding Study of Zoledronate in Hypercalcemic Cancer Patients
JOURNAL OF BONE AND MINERAL RESEARCH Volume 14, Number 9, 1999 Blackwell Science, Inc. 1999 American Society for Bone and Mineral Research A Dose-Finding Study of Zoledronate in Hypercalcemic Cancer Patients
More informationScottish Medicines Consortium
Scottish Medicines Consortium zoledronic acid 5mg/100ml solution for infusion (Aclasta) No. (317/06) Novartis 8 September 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationCALCIUM BALANCE. James T. McCarthy & Rajiv Kumar
CALCIUM BALANCE James T. McCarthy & Rajiv Kumar CALCIUM BALANCE TOTAL BODY CALCIUM (~ 1000g in a normal 60 kg adult) - > 99% in bones - ~ 0.6% in the intracellular space - ~ 0.1% in the extracellular space
More informationCHRONIC KIDNEY DISEASE (CKD)
CHRONIC KIDNEY DISEASE (CKD) CKD implies longstanding (more than 3 months), and usually progressive, impairment in renal function. In many instances, no effective means are available to reverse the primary
More informationGUIDELINES ON THE USE OF BISPHOSPHONATES IN PALLIATIVE CARE. November 2007(Amended July 2008)
Yorkshire Palliative Medicine Clinical Guidelines Group GUIDELINES ON THE USE OF BISPHOSPHONATES IN PALLIATIVE CARE November 2007(Amended July 2008) Authors: Dr Kath Lambert and Dr Liz Brown, on behalf
More informationQuestions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss. A Publication of The Bone and Cancer Foundation
Questions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss A Publication of The Bone and Cancer Foundation Contents This publication includes important information about
More informationChapter. Contents Breast Cancer Adjuvant Epirubicin weekly. Docetaxel Copy No:
Chapter 2: Breast Cancer Contents Chapter 2: Breast Cancer... 1 Breast Cancer... 2 Adjuvant...... 2 Epi-CMF... 2 FEC / docetaxel... 3 FEC100... 4 AC/EC/TC... 4 (neo) adjuvant... 5... 5 HER2 positive: TCarboH...
More informationSaint-Antoine Hospital, Paris. Medical Intensive Unit Care. Hafid Ait-Oufella, MD.PhD. Dyscalcemia. Dyskalemia
Dyskalemia Dyscalcemia Hafid Ait-Oufella, MD.PhD. Medical Intensive Unit Care Saint-Antoine Hospital, Paris Potassium K + Molecular weight: 39 1gr K + =2.5mmol Potassium disorders in ICU : Our experience
More informationCurrent Management of Metastatic Bone Disease
Current Management of Metastatic Bone Disease Evaluation and Medical Management Dr. Sara Rask Head, Medical Oncology Simcoe Muskoka Regional Cancer Centre www.rvh.on.ca Objectives 1. Outline an initial
More informationDENOSUMAB (PROLIA & XGEVA )
DENOSUMAB (PROLIA & XGEVA ) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 306.3 T2 Effective Date: July 2, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationMr PA. Clinical assessment of hydration. Poor urine output Sunken eyes Moistness of mucosa Cool peripheries Reduction in weight Postural hypotension
X Anthony Warrens Mr PA 54 years old Previously well Went to Thailand Developed serious diarrhoea and vomiting two days before coming home 24 hours after return, still unwell GP found: urea 24 mmol/l creatinine
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Zoledronic acid Therapeutic Area of Trial Breast cancer, prostrate cancer Approved Indication Prevention of skeletal related events
More informationIdentification of the Risk Factors of Bone Metastatic among Breast Cancer Women in Al-Bashir Hospital
Advances in Breast Cancer Research, 2018, 7, 120-129 http://www.scirp.org/journal/abcr ISSN Online: 2168-1597 ISSN Print: 2168-1589 Identification of the Risk Factors of Bone Metastatic among Breast Cancer
More informationQuestions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss. A Publication of The Bone and Cancer Foundation
Questions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss A Publication of The Bone and Cancer Foundation Contents This publication includes important information about
More informationAcid-Base Balance 11/18/2011. Regulation of Potassium Balance. Regulation of Potassium Balance. Regulatory Site: Cortical Collecting Ducts.
Influence of Other Hormones on Sodium Balance Acid-Base Balance Estrogens: Enhance NaCl reabsorption by renal tubules May cause water retention during menstrual cycles Are responsible for edema during
More informationDistal renal tubular acidosis: genetic and clinical spectrum
Distal renal tubular acidosis: genetic and clinical spectrum Sabrina Giglio Medical Genetics Unit, Meyer Children s University Hospital, University of Florence sabrina.giglio@meyer.it sabrinarita.giglio@unifi.it
More informationCalcium (Ca 2+ ) mg/dl
Quick Guide to Laboratory Values Use this handy cheat-sheet to help you monitor laboratory values related to fluid and electrolyte status. Remember, normal values may vary according to techniques used
More informationRISK FACTORS AND TREATMENT STRATEGIES FOR URINARY STONES Review of NASA s Evidence Reports on Human Health Risks
Mayo Clinic O Brien Urology Research Center RISK FACTORS AND TREATMENT STRATEGIES FOR URINARY STONES 2017 Review of NASA s Evidence Reports on Human Health Risks John C Lieske, MD July 27, 2017 What types
More informationFanconi-like syndrome and rhabdomyolysis in a person with HIV infection. on highly active antiretroviral treatment including tenofovir
1 Letter to the Editor Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir The nucleotide analogue, tenofovir disoproxil
More informationINTRAVENOUS FLUID THERAPY
INTRAVENOUS FLUID THERAPY PRINCIPLES Postnatal physiological weight loss is approximately 5 10% in first week of life Preterm neonates have more total body water and may lose 10 15% of their weight in
More informationTNU QUIZ. Affiliation: 1. Presence of the following may indicate non-diabetic kidney disease in a patient with type 2 diabetes mellitus:
TNU QUIZ Name: Affiliation: Print, Answer and Deliver it to the registration desk on Thursday 8 th November 2018 before 11 am 1. Presence of the following may indicate non-diabetic kidney disease in a
More informationDiabetes, Obesity and Heavy Proteinuria
Diabetes, Obesity and Heavy Proteinuria Clinical Case 41 yo Black woman with heavy proteinuria History 2014: noted to have proteinuria on routine lab testing (1.1g/g). 1+ edema. Blood pressure has been
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationRipamonti C, et al. ASCO 2012 (Abstract 9005)
ZOOM: A Prospective, Randomized Trial of Zoledronic Acid for Long-term Treatment in Patients With Bone-Metastatic Breast Cancer After 1 Year of Standard Zoledronic Acid Treatment D. Amadori, M. Aglietta,
More information5/10/2014. Observation, control of blood pressure. Observation, control of blood pressure and risk factors.
Overview The Kidneys Nicola Barlow Clinical Biochemistry Department City Hospital Renal physiology Renal pathophysiology Acute kidney injury Chronic kidney disease Assessing renal function GFR Proteinuria
More informationSchool of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PLB SEMINAR
1 School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PLB SEMINAR URINARY (RENAL) STONE FORMATION An Overview What are Urinary (Renal)
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationAmjad Bani Hani Ass.Prof. of Cardiac Surgery & Intensive Care FLUIDS AND ELECTROLYTES
Amjad Bani Hani Ass.Prof. of Cardiac Surgery & Intensive Care FLUIDS AND ELECTROLYTES Body Water Content Water Balance: Normal 2500 2000 1500 1000 500 Metab Food Fluids Stool Breath Sweat Urine
More informationDiabetic Ketoacidosis
Diabetic Ketoacidosis Definition: Diabetic Ketoacidosis is one of the most serious acute complications of diabetes. It s more common in young patients with type 1 diabetes mellitus. It s usually characterized
More informationSource of effectiveness data The effectiveness evidence was derived from a single study that was identified from a review of the literature.
Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK Guest J F, Clegg J P, Davie A M, McCloskey E Record Status This is a critical
More informationInstrumental determination of electrolytes in urine. Amal Alamri
Instrumental determination of electrolytes in urine Amal Alamri What is the Electrolytes? Electrolytes are positively and negatively chargedions, Found in Within body's cells extracellular fluids, including
More informationNephrology - the study of the kidney. Urology - branch of medicine dealing with the male and female urinary systems and the male reproductive system
Urinary System Nephrology - the study of the kidney Urology - branch of medicine dealing with the male and female urinary systems and the male reproductive system Functions of the Urinary System 1. Regulation
More informationMajor intra and extracellular ions Lec: 1
Major intra and extracellular ions Lec: 1 The body fluids are solutions of inorganic and organic solutes. The concentration balance of the various components is maintained in order for the cell and tissue
More informationELECTROLYTE DISTURBANCES AND ABNORMAL URINE ANALYSIS IN CHILDREN WITH DENGUE INFECTION
ELECTROLYTE DISTURBANCES AND ABNORMAL URINE ANALYSIS IN CHILDREN WITH DENGUE INFECTION Adisorn Lumpaopong 1, Pinyada Kaewplang 1, Veerachai Watanaveeradej 2, Prapaipim Thirakhupt 1, Sangkae Chamnanvanakij
More informationKey Questions: What are the
The Case of Kensington s Calcium Gregory K. Ogilvie, DVM Diplomate ACVIM (Specialties of Internal Medicine, Oncology) Diplomate ECVIM-CA (Oncology) CVS Angel Care Cancer Center University of California
More informationKeywords Breast cancer Brain metastasis Lapatinib Capecitabine. Introduction
Int Canc Conf J (2013) 2:9 13 DOI 10.1007/s13691-012-0054-x CASE REPORT HER2-positive recurrent breast cancer and metastases of breast cancer, including life-threatening metastases to the brain and dura
More informationZerlinda (MRP DK/H/2265/001)
Zerlinda (MRP DK/H/2265/001) VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Prevention of bone complications, e.g. fractures, in adult patients with bone metastases (spread
More informationFocal segmental glomerulosclerosis (FSGS) is a histological. Reversibility of pamidronate-associated glomerulosclerosis
Reversibility of pamidronate-associated glomerulosclerosis Meera Shreedhara, MD, Andrew Z. Fenves, MD, Diana Benavides, MD, and Marvin J. Stone, MD, MACP Bisphosphonates such as pamidronate are widely
More informationACID/BASE. A. What is her acid-base disorder, what is her anion gap, and what is the likely cause?
These fluid and electrolyte problems are modified from those in a previous textbook for this sequence, Renal Pathophysiology edited by James A. Shayman M.D., Professor of Internal Medicine, University
More informationPrior Authorization Required: Yes as shown below
PROLIA, XGEVA (denosumab) MB9409 Covered Service: Prior Authorization Required: Additional Information Medicare Policy: BadgerCare Plus Policy: Yes when meets criteria below Yes as shown below Must be
More informationKidneycentric. Follow this and additional works at:
Washington University School of Medicine Digital Commons@Becker All Kidneycentric 2014 Gitelman syndrome David Steflik Washington University School of Medicine in St. Louis Follow this and additional works
More informationGuidelines for approach to a child with
Guidelines for approach to a child with Metabolic acidosis (including RTA) Children s Kidney Centre University Hospital of Wales Cardiff CF14 4XW DISCLAIMER: These guidelines were produced in good faith
More informationPhiladelphia College of Osteopathic Medicine. Dara Colasurdo Philadelphia College of Osteopathic Medicine,
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Does The Use Of Intravenous Zoledronic
More informationMultiple myeloma, nephrotic syndrome and crystalloid inclusions in podocytes
the renal consult http://www.kidney-international.org & 2006 International Society of Nephrology Multiple myeloma, nephrotic syndrome and crystalloid inclusions in podocytes SH Nasr 1, DC Preddie 2, GS
More informationTHERAPEUTIC EFFICACY AND PHARMACOECONOMICS EVAULATION OF PAMIDRONATE VERSUS ZOLEDRONIC ACID IN MULTIPLE MYELOMA PATIENTS
438 J App Pharm 04(03): 438-452 (2011) Qasim et al., 2011 ORIGINAL ARTICLE THERAPEUTIC EFFICACY AND PHARMACOECONOMICS EVAULATION OF PAMIDRONATE VERSUS ZOLEDRONIC ACID IN MULTIPLE MYELOMA PATIENTS Saima
More informationAlterations of Renal and Urinary Tract Function
Alterations of Renal and Urinary Tract Function Chapter 29 Urinary Tract Obstruction Urinary tract obstruction is an interference with the flow of urine at any site along the urinary tract The obstruction
More informationDisorders of the kidney. Urine analysis. Nephrotic and nephritic syndrome.
Disorders of the kidney. Urine analysis. Nephrotic and nephritic syndrome. Azotemia and Urinary Abnormalities Disturbances in urine volume oliguria, anuria, polyuria Abnormalities of urine sediment red
More informationNATURAL HISTORY AND SURVIVAL OF PATIENTS WITH ASCITES. PATIENTS WHO DO NOT DEVELOP COMPLICATIONS HAVE MARKEDLY BETTER SURVIVAL THAN THOSE WHO DEVELOP
PROGNOSIS Mortality rates as high as 18-30% are reported for hyponatremic patients. High mortality rates reflect the severity of underlying conditions and are not influenced by treatment of hyponatremia
More informationNab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review
Acta Biomed 2017; Vol. 88, N. 3: 329-333 DOI: 10.23750/abm.v%vi%i.6138 Mattioli 1885 Case report Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review Benedetta Pellegrino
More informationBisphosphonate Treatment Recommendations for Oncologists
Bisphosphonate Treatment Recommendations for Oncologists Roger von Moos Rätisches Kantons- und Regionalspital, Chur, Switzerland Key Words. Bisphosphonates Ibandronate Renal safety Product labeling Product
More informationProceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009
www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers HOW
More informationThe efficacy of magnesium in preventing renal dysfunction due to high-dose cisplatin for treatment of thoracic tumor
Acta Med. Nagasaki 0: 39 44 MS#AMN 07171 The efficacy of magnesium in preventing renal dysfunction due to high-dose cisplatin for treatment of thoracic tumor Kohei Mo t o s h i m a 1, Yoichi Na k a m u
More information